| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 80, 3246-3256, Copyright © 1995 by Endocrine Society
ARTICLES |
Y Hayashi, RE Weiss, DH Sarne, PM Yen, T Sunthornthepvarakul, C Marcocci, WW Chin and S Refetoff
Department of Medicine, University of Chicago, Illinois 60637, USA.
Resistance to thyroid hormone (RTH), a syndrome characterized by variable tissue hyposensitivity to thyroid hormone, is linked to mutations in the thyroid hormone receptor-beta (TR beta) gene. The purpose of this study was to determine whether the clinical phenotypes of RTH can be translated in terms of functional impairment of the corresponding mutant TR beta. Data from 124 subjects with RTH representing 18 different mutant TR beta s, showed that serum free T4 levels correlated with the degree of T3-binding impairment of the corresponding TR beta in 12 of these mutant TR beta s (group I), but not in the remaining 6 (group II). In subjects from both groups studied in detail by the administration of incremental doses of T3, the degree of thyrotroph resistance to T3 correlated with the magnitude of endogenous free T4 elevation at baseline, but did not parallel the resistance of peripheral tissues. In transfection studies, all group I mutant TR beta s inhibited positive transactivation by the wild type TR beta s to a similar degree in the presence of 1 nmol/L T3, whereas group II mutant TR beta s exerted a weaker inhibition that was not related to their T3-dependent trans-activation when tested alone. Similar results were obtained with negatively regulated reporter genes. It is concluded that the clinical severity of RTH, determined by thyrotroph resistance, can be predicted from the degree of T3 binding impairment and dominant negative potency of mutant TR beta s, but the degree of peripheral tissue resistance and related clinical manifestations is limited by putative genetic or environmental factors that modulate the effect of thyroid hormone.
This article has been cited by other articles:
 |
|
 |
|
  S. Mamanasiri, S. Yesil, A. M. Dumitrescu, X.-H. Liao, T. Demir, R. E. Weiss, and S. Refetoff Mosaicism of a Thyroid Hormone Receptor-{beta} Gene Mutation in Resistance to Thyroid Hormone J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3471 - 3477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Y. Wu, R. N. Cohen, E. Simsek, D. A. Senses, N. E. Yar, H. Grasberger, J. Noel, S. Refetoff, and R. E. Weiss A Novel Thyroid Hormone Receptor-{beta} Mutation That Fails to Bind Nuclear Receptor Corepressor in a Patient as an Apparent Cause of Severe, Predominantly Pituitary Resistance to Thyroid Hormone J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1887 - 1895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lado-Abeal, A. M. Dumitrescu, X.-H. Liao, R. N. Cohen, J. Pohlenz, R. E. Weiss, M.-C. Lebrethon, A. Verloes, and S. Refetoff A De Novo Mutation in an Already Mutant Nucleotide of the Thyroid Hormone Receptor {beta} Gene Perpetuates Resistance to Thyroid Hormone J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1760 - 1767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Agostini, M. Gurnell, D. B. Savage, E. M. Wood, A. G. Smith, O. Rajanayagam, K. T. Garnes, S. H. Levinson, H. E. Xu, J. W. R. Schwabe, et al. Tyrosine Agonists Reverse the Molecular Defects Associated with Dominant-Negative Mutations in Human Peroxisome Proliferator-Activated Receptor {gamma} Endocrinology, April 1, 2004; 145(4): 1527 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Huber, B. Sandler, B. L. West, S. T. Cunha Lima, H. T. Nguyen, J. W. Apriletti, J. D. Baxter, and R. J. Fletterick Two Resistance to Thyroid Hormone Mutants with Impaired Hormone Binding Mol. Endocrinol., April 1, 2003; 17(4): 643 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Huber, M. Desclozeaux, B. L. West, S. T. Cunha-Lima, H. T. Nguyen, J. D. Baxter, H. A. Ingraham, and R. J. Fletterick Thyroid Hormone Receptor-{beta} Mutations Conferring Hormone Resistance and Reduced Corepressor Release Exhibit Decreased Stability in the N-Terminal Ligand-Binding Domain Mol. Endocrinol., January 1, 2003; 17(1): 107 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Kahaly, C. H. Matthews, S. Mohr-Kahaly, C. A. Richards, and V. K. K. Chatterjee Cardiac Involvement in Thyroid Hormone Resistance J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 204 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Anselmo, T. Kay, K. Dennis, R. Szmulewitz, S. Refetoff, and R. E. Weiss Resistance to Thyroid Hormone Does Not Abrogate the Transient Thyrotoxicosis Associated with Gestation: Report of a Case J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4273 - 4275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Yen Physiological and Molecular Basis of Thyroid Hormone Action Physiol Rev, July 1, 2001; 81(3): 1097 - 1142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Reutrakul, P. M. Sadow, S. Pannain, J. Pohlenz, G. A. Carvalho, P. E. Macchia, R. E. Weiss, and S. Refetoff Search for Abnormalities of Nuclear Corepressors, Coactivators, and a Coregulator in Families with Resistance to Thyroid Hormone without Mutations in Thyroid Hormone Receptor {beta} or {alpha} Genes J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3609 - 3617. [Abstract] [Full Text]
|
|
|
|
|
|
S. Ercan-Fang, H. L. Schwartz, C. N. Mariash, and J. H. Oppenheimer Quantitative Assessment of Pituitary Resistance to Thyroid Hormone from Plots of the Logarithm of Thyrotropin Versus Serum Free Thyroxine Index J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2299 - 2303. [Abstract] [Full Text]
|
|
|
|
|
|
M. Gurnell, O. Rajanayagam, M. Agostini, R. J. D. Clifton-Bligh, T. Wang, P. M. J. Zelissen, F. van der Horst, A. v. d. Wiel, E. Macchia, A. Pinchera, et al. Three Novel Mutations at Serine 314 in the Thyroid Hormone {beta} Receptor Differentially Impair Ligand Binding in the Syndrome of Resistance to Thyroid Hormone Endocrinology, December 1, 1999; 140(12): 5901 - 5906. [Abstract] [Full Text]
|
|
|
|
|
|
J. Pohlenz, R. E. Weiss, P. E. Macchia, S. Pannain, I. T. Lau, H. Ho, and S. Refetoff Five New Families with Resistance to Thyroid Hormone not Caused by Mutations in the Thyroid Hormone Receptor {beta} Gene J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 3919 - 3928. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. K. Kim, J.-S. Lee, and J. H. Chung In vivo transcription factor recruitment during thyroid hormone receptor-mediated activation PNAS, August 31, 1999; 96(18): 10092 - 10097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Weiss and S. Refetoff Editorial: Treatment of Resistance to Thyroid Hormone--Primum Non Nocere J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 401 - 404. [Full Text]
|
|
|
|
|
|
C. Asteria, O. Rajanayagam, T. N. Collingwood, L. Persani, R. Romoli, D. Mannavola, P. Zamperini, F. Buzi, F. Ciralli, V. K. K. Chatterjee, et al. Prenatal Diagnosis of Thyroid Hormone Resistance J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 405 - 410. [Abstract] [Full Text]
|
|
|
|
|
|
T. Tagami, W.-X. Gu, P. T. Peairs, B. L. West, and J. L. Jameson A Novel Natural Mutation in the Thyroid Hormone Receptor Defines a Dual Functional Domain That Exchanges Nuclear Receptor Corepressors and Coactivators Mol. Endocrinol., December 1, 1998; 12(12): 1888 - 1902. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Liu, A. Takeshita, S. Misiti, W. W. Chin, and P. M. Yen Lack of Coactivator Interaction Can Be a Mechanism for Dominant Negative Activity by Mutant Thyroid Hormone Receptors Endocrinology, October 1, 1998; 139(10): 4197 - 4204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Clifton-Bligh, F. de Zegher, R. L. Wagner, T. N. Collingwood, I. Francois, M. Van Helvoirt, R. J. Fletterick, and V. K. K. Chatterjee A Novel TR{beta} Mutation (R383H) in Resistance to Thyroid Hormone Syndrome Predominantly Impairs Corepressor Release and Negative Transcriptional Regulation Mol. Endocrinol., May 1, 1998; 12(5): 609 - 621. [Abstract] [Full Text]
|
|
|
|
|
|
T. Tagami and J. L. Jameson Nuclear Corepressors Enhance the Dominant Negative Activity of Mutant Receptors That Cause Resistance to Thyroid Hormone Endocrinology, February 1, 1998; 139(2): 640 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu, A. Takeshita, T. Nagaya, A. Baniahmad, W. W. Chin, and P. M. Yen An Inhibitory Region of the DNA-Binding Domain of Thyroid Hormone Receptor Blocks Hormone-Dependent Transactivation Mol. Endocrinol., January 1, 1998; 12(1): 34 - 44. [Abstract] [Full Text]
|
|
|
|
|
|
S. I. Sherman, M. D. Ringel, M. J. Smith, H. A. Kopelen, W. A. Zoghbi, and P. W. Ladenson Augmented Hepatic and Skeletal Thyromimetic Effects of Tiratricol in Comparison with Levothyroxine J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2153 - 2158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yagi, J. Pohlenz, Y. Hayashi, A. Sakurai, and S. Refetoff Resistance to Thyroid Hormone Caused by Two Mutant Thyroid Hormone Receptors {beta}, R243Q and R243W, with Marked Impairment of Function That Cannot Be Explained by Altered in Vitro 3,5,3'-Triiodothyroinine Binding Affinity J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1608 - 1614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Yoh, V. K. K. Chatterjee, and M. L. Privalsky Thyroid Hormone Resistance Syndrome Manifests as an Aberrant Interaction between Mutant T3 Receptors and Transcriptional Corepressors Mol. Endocrinol., April 1, 1997; 11(4): 470 - 480. [Abstract] [Full Text]
|
|
|
|
|
|
J. D. Safer, M. F. Langlois, R. Cohen, T. Monden, D. John-Hope, J. Madura, A. N. Hollenberg, and F. E. Wondisford Isoform Variable Action among Thyroid Hormone Receptor Mutants Provides Insight into Pituitary Resistance to Thyroid Hormone Mol. Endocrinol., January 1, 1997; 11(1): 16 - 26. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
